This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NVIV InVivo Therapeutics (NVIV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About InVivo Therapeutics Stock (NASDAQ:NVIV) 30 days 90 days 365 days Advanced Chart Get InVivo Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.22▼$0.7952-Week Range N/AVolume1.89 million shsAverage Volume8.25 million shsMarket Capitalization$997 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation. Read More Receive NVIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NVIV Stock News HeadlinesSpinal Cord Injury Treatment Market Size to Worth USD 11 Bn by 2032August 9, 2024 | finance.yahoo.comInVivo Therapeutics Holdings Co (NVIVQ)May 26, 2024 | finance.yahoo.comA $674B Industry Missed the Bigger PictureTV video streaming exploded into a $674.25B market in 2024—driven by the hours we spend lost in entertainment. But there’s a much bigger habit consuming our time, with value that’s waiting to be unlocked. Smartphone screen time. We spend over 30 hours a week glued to our phones. Mode Mobile is pioneering ways to turn those hours into real income. Their EarnPhone unlocks 19 revenue streams from everyday phone use, helping users earn over $325M so far. Deloitte crowned them North America’s fastest-growing software company in 2023 after their revenue soared 32,481% from 2019-2022. But this industry is still in its infancy, and you can invest in the company that’s at the forefront of unlocking its value.July 30 at 2:00 AM | Mode Mobile (Ad)InVivo Therapeutics Holdings Corp (NVIVQ)May 17, 2024 | investing.comGut health supplements are everywhere – but which are the best ones for *you*?March 28, 2024 | msn.comInVivo Therapeutics Holdings CorporationFebruary 14, 2024 | cnn.comInVivo Therapeutics Holdings Corp.February 14, 2024 | wsj.comFirm Retention Summary: InVivo Therapeutics HoldingsFebruary 13, 2024 | wsj.comSee More Headlines NVIV Stock Analysis - Frequently Asked Questions How were InVivo Therapeutics' earnings last quarter? InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) issued its quarterly earnings results on Wednesday, May, 13th. The biotechnology company reported ($61.75) earnings per share (EPS) for the quarter. When did InVivo Therapeutics' stock split? InVivo Therapeutics shares reverse split before market open on Wednesday, April 27th 2022.The 1-25 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of InVivo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that InVivo Therapeutics investors own include Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Tonix Pharmaceuticals (TNXP), Flexion Therapeutics (FLXN), OPKO Health (OPK), Acasti Pharma (ACST) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings5/13/2020Today7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NVIV CIK1292519 Webwww.invivotherapeutics.com Phone(617) 863-5500FaxN/AEmployees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.49 million Net MarginsN/A Pretax MarginN/A Return on Equity-75.04% Return on Assets-65.01% Debt Debt-to-Equity RatioN/A Current Ratio14.30 Quick Ratio14.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.48 per share Price / BookN/AMiscellaneous Outstanding Shares3,110,000Free Float3,029,000Market Cap$997 thousand OptionableNot Optionable Beta0.65 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:NVIV) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThe Fed Just Froze You Out (Again)The Fed’s holding rates steady—again. No clarity. No yield. No relief. But one income strategy is quietly t...Investors Alley | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredSomething BIG is about to hit the stock marketMost investors won’t see it coming—but Weiss Ratings says a major market event is brewing. Their system jus...Weiss Ratings | SponsoredThe $1 Trillion Event Tesla Still Hasn’t Recovered FromIn 2010, a “Flash Crash” erased $1 trillion in minutes. Now, one trading legend says it’s happening again—insi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InVivo Therapeutics Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share InVivo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.